

Rare Haematology Disorders Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Rare Haematology Disorders Market Report and Forecast 2024-2032

The global rare haematology disorders market was valued at USD 17 billion in 2023. It is expected to grow at a CAGR of 6.2% in the forecast period of 2024-2032 and attain a market value of USD 65.6 billion by 2032.

Global Rare Haematology Disorders Market Analysis

The global rare haematology disorders market encompasses a diverse group of blood-related diseases that affect a small percentage of the population. These disorders include conditions such as haemophilia, sickle cell anaemia, thalassaemia, and other rare blood clotting and bleeding disorders. The market has seen significant growth in recent years, driven by increased awareness, advancements in diagnostic technologies, and the development of innovative therapies. Despite the rarity of these conditions, they pose significant health challenges for patients, making the demand for effective treatments and management strategies crucial.

Market Drivers

Several factors are driving the growth of the global rare haematology disorders market. One of the primary drivers is the increasing prevalence of rare blood disorders due to improved diagnostic capabilities. Early and accurate diagnosis has led to better disease management and an increased focus on treatment development. Additionally, technological advancements in gene therapy and targeted therapies are transforming the treatment landscape, offering hope for more effective and personalised treatments for patients with rare haematology disorders.

Government initiatives and funding aimed at rare disease research have also played a crucial role in market growth. Programmes that incentivise the development of orphan drugs-medications designed specifically for rare diseases-have encouraged pharmaceutical companies to invest in this market. Moreover, the growing patient advocacy and support networks are raising

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

awareness and driving demand for better treatment options, leading to increased market expansion.

Market Challenges

Despite the positive growth trajectory, the global rare haematology disorders market faces several challenges. One of the major hurdles is the high cost of treatment. Many therapies, especially gene and enzyme replacement therapies, are expensive, making them inaccessible to a significant portion of the population, particularly in low- and middle-income countries. Additionally, the complex regulatory landscape for the approval of orphan drugs can delay the introduction of new treatments, hindering market growth.

Another challenge is the limited patient population, which makes it difficult to conduct large-scale clinical trials and gather sufficient data for the development of new therapies. This limitation often results in a lack of comprehensive treatment options and a slow pace of innovation in the field. Furthermore, awareness of rare haematology disorders remains low in certain regions, leading to delayed diagnosis and treatment.

Future Opportunities

The future of the global rare haematology disorders market looks promising, with several opportunities for growth and innovation. Emerging markets offer significant potential as healthcare infrastructure improves and awareness of rare disorders increases. As governments in these regions allocate more resources to healthcare, the accessibility of advanced treatments is expected to rise.

The development of gene editing technologies, such as CRISPR-Cas9, presents a groundbreaking opportunity for curing or significantly mitigating the effects of rare haematology disorders. These technologies have the potential to offer long-term solutions and even permanent cures, revolutionising the treatment landscape.

Collaborative research efforts between academic institutions, pharmaceutical companies, and patient advocacy groups are likely to accelerate the development of new therapies. These partnerships can lead to more efficient drug development processes and bring innovative treatments to market faster.

Lastly, digital health solutions and telemedicine offer new ways to manage rare haematology disorders, particularly in remote areas. These technologies can improve patient monitoring, enhance access to specialist care, and support the ongoing management of these complex conditions.

Global Rare Haematology Disorders Market Trends

The global rare haematology disorders market is evolving rapidly, influenced by technological advancements, increased awareness, and a growing emphasis on personalised medicine. As the landscape shifts, several key trends are shaping the future of this specialised market.

- 1. Gene and Cell Therapies Leading the Way:** The rise of gene and cell therapies is a significant trend in the rare haematology disorders market. These cutting-edge treatments offer the potential to address the root cause of many rare blood disorders by correcting genetic abnormalities or replacing defective cells. The success of therapies like gene editing and CAR-T cell treatments is paving the way for more personalised and long-lasting solutions, which are expected to become the standard of care in the coming years.
- 2. Expansion of Orphan Drug Designations:** The increasing number of orphan drug designations is driving innovation in the market. Regulatory incentives, including market exclusivity and tax benefits, are encouraging pharmaceutical companies to invest

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

in the development of treatments for rare haematology disorders. This trend is leading to a more robust pipeline of therapies, with several promising drugs expected to receive approval in the near future.

3. Growth in Patient Advocacy and Support Networks: Patient advocacy groups are playing a crucial role in the rare haematology disorders market by raising awareness, influencing policy, and driving research initiatives. These organisations are increasingly partnering with pharmaceutical companies and research institutions to accelerate the development of new treatments and improve patient access to care. This growing collaboration is helping to bridge the gap between patients and treatment providers, leading to better outcomes and more comprehensive care.

4. Adoption of Advanced Diagnostic Technologies: Advances in diagnostic technologies, such as next-generation sequencing and molecular diagnostics, are transforming the way rare haematology disorders are identified and managed. Early and accurate diagnosis is becoming more achievable, enabling healthcare providers to implement targeted treatment plans more quickly. This trend is expected to reduce the burden of misdiagnosis and improve the overall prognosis for patients with rare blood disorders.

5. Increased Focus on Precision Medicine: Precision medicine is gaining traction in the rare haematology disorders market, with treatments increasingly tailored to the specific genetic and molecular profiles of patients. This approach is leading to more effective therapies with fewer side effects, as well as a shift towards personalised treatment strategies that cater to individual patient needs. As precision medicine continues to advance, it is expected to become a cornerstone of care for patients with rare haematology disorders.

Global Rare Haematology Disorders Market Segmentation

Market Breakup by Treatment Type

Plasma Derived

Recombinant

The plasma-derived and recombinant treatment segments are crucial drivers in the rare haematology disorders market. Plasma-derived treatments, long established in the market, are essential for managing conditions like haemophilia. However, the recombinant segment is witnessing rapid growth due to its reduced risk of pathogen transmission and enhanced efficacy. The increasing adoption of recombinant therapies, driven by technological advancements and patient preference for safer options, is expected to significantly propel market growth. As more innovative recombinant treatments enter the market, this segment is poised to drive the overall market expansion during the forecast period.

Market Breakup by Disease Type

Langerhans Cell Histiocytosis (LCH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Gaucher Disease

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Polycythemia Vera

Others

The rare haematology disorders market is diversified across various disease types, each contributing to the market's growth. Langerhans Cell Histiocytosis (LCH) and Paroxysmal Nocturnal Haemoglobinuria (PNH) are receiving increased attention due to advancements in targeted therapies, driving their market segments. Gaucher Disease and Polycythaemia Vera are also witnessing growth, supported by improved diagnostic methods and innovative treatment options. The "Others" category includes various ultra-rare conditions that, although smaller in patient population, benefit from orphan drug development and regulatory incentives. Collectively, these segments are expected to drive significant market growth during the forecast period.

Market Breakup by Dosage Form

Oral

Injectable

Others

The dosage form segmentation of the rare haematology disorders market reveals distinct growth patterns. The oral segment is gaining traction due to patient preference for ease of administration and improved compliance, particularly with advancements in oral formulations for rare conditions. However, the injectable segment remains dominant, driven by its necessity for administering biologics and gene therapies, which are critical for many rare haematological conditions. The "Others" category, encompassing novel delivery methods like transdermal patches and nasal sprays, is also emerging, offering alternative options for patients. Together, these segments are poised to drive market growth, with injectables continuing to lead during the forecast period.

Market Breakup by Age Group

Adult (18+)

Pediatric (0-17)

The rare haematology disorders market is segmented by age group into adult and paediatric populations, each presenting unique dynamics. The adult segment dominates the market, driven by a higher prevalence of certain rare blood disorders in this age group, along with more extensive treatment options and clinical trials tailored to adults. However, the paediatric segment is also experiencing growth, fuelled by increased focus on early diagnosis and treatment, along with advancements in paediatric-specific therapies. As awareness and research in paediatric rare haematology disorders expand, this segment is poised to contribute

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

significantly to market growth during the forecast period.

Market Breakup by Region

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

The rare haematology disorders market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, each contributing to market dynamics in distinct ways. North America leads the market, driven by advanced healthcare infrastructure, high research and development activity, and strong regulatory support for orphan drugs. Europe follows closely, benefiting from robust healthcare systems and extensive patient support networks. Asia Pacific is witnessing rapid growth due to increasing awareness, improving healthcare access, and rising investment in research. Latin America and the Middle East and Africa are emerging markets, with growth driven by improving healthcare infrastructure and rising focus on rare disease management. Collectively, these regions are expected to drive substantial market growth during the forecast period.

Global Rare Haematology Disorders Market Competitive Landscape

The competitive landscape of the global rare haematology disorders market is characterised by the presence of several key players, including Bristol-Myers Squibb Company, Novo Nordisk, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., Octapharma, Novartis, Grifols, CSL Behring, and Takeda. These companies are actively engaged in market-shaping activities such as mergers and acquisitions, research and development initiatives, new product introductions, and strategic partnerships. These activities aim to expand their product portfolios, enhance market presence, and drive innovation in the treatment of rare haematology disorders. The competitive environment is dynamic, with companies striving to gain a competitive edge through advancements in gene therapy, biologics, and orphan drug development, positioning them as leaders in this specialised market.

Key Questions Answered in the Report

What is the current and future performance of the global rare haematology disorders market?

What are the main challenges facing the global rare haematology disorders market?

What are the key drivers of the global rare haematology disorders market?

What emerging trends are shaping the future of the global rare haematology disorders market?

How are advances in diagnostic technologies improving the early detection of rare haematology disorders?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

How is precision medicine transforming treatment strategies in the rare haematology disorders market?

What factors are driving the rapid growth of the recombinant segment in the rare haematology disorders market?

Which disease types are gaining attention in the rare haematology disorders market, and why?

Why does the adult segment dominate the rare haematology disorders market?

What are the common strategies used by key players in the global rare haematology disorders market?

Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the rare haematology disorders market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the rare haematology disorders market.

The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the rare haematology disorders industry and its attractiveness.

The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Rare Haematology Disorders Market Overview
 - 3.1 Global Rare Haematology Disorders Market Historical Value (2017-2023)
 - 3.2 Global Rare Haematology Disorders Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Global Rare Haematology Disorders Market Landscape*
 - 5.1 Global Rare Haematology Disorders: Developers Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.1□Analysis by Year of Establishment
- 5.1.2□Analysis by Company Size
- 5.1.3□Analysis by Region
- 5.2□Global Rare Haematology Disorders: Product Landscape
- 5.2.1□Analysis by Treatment Type
- 6□Global Rare Haematology Disorders Market Dynamics
- 6.1□Market Drivers and Constraints
- 6.2□SWOT Analysis
- 6.2.1□Strengths
- 6.2.2□Weaknesses
- 6.2.3□Opportunities
- 6.2.4□Threats
- 6.3□PESTEL Analysis
- 6.3.1□Political
- 6.3.2□Economic
- 6.3.3□Social
- 6.3.4□Technological
- 6.3.5□Legal
- 6.3.6□Environment
- 6.4□Porter's Five Forces Model
- 6.4.1□Bargaining Power of Suppliers
- 6.4.2□Bargaining Power of Buyers
- 6.4.3□Threat of New Entrants
- 6.4.4□Threat of Substitutes
- 6.4.5□Degree of Rivalry
- 6.5□Key Demand Indicators
- 6.6□Key Price Indicators
- 6.7□Industry Events, Initiatives, and Trends
- 6.8□Value Chain Analysis
- 7□Global Rare Haematology Disorders Market Segmentation (2017-2032)
- 7.1□Global Rare Haematology Disorders Market (2017-2032) by Treatment Type
- 7.1.1□Market Overview
- 7.1.2□Plasma Derived
- 7.1.3□Recombinant
- 7.2□Global Rare Haematology Disorders Market (2017-2032) by Disease Type
- 7.2.1□Market Overview
- 7.2.2□Langerhans Cell Histiocytosis (LCH)
- 7.2.3□Paroxysmal Nocturnal Hemoglobinuria (PNH)
- 7.2.4□Gaucher Disease
- 7.2.5□Polycythemia Vera
- 7.2.6□Others
- 7.3□Global Rare Haematology Disorders Market (2017-2032) by Dosage Form
- 7.3.1□Market Overview
- 7.3.2□Oral
- 7.3.3□Injectable
- 7.3.4□Others
- 7.4□Healthcare Global Rare Haematology Disorders Market (2017-2032) by Age Group

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.1 Market Overview
- 7.4.2 Adult (18+)
- 7.4.3 Pediatric (0-17)
- 7.5 Global Rare Haematology Disorders Market (2017-2032) by Region
 - 7.5.1 Market Overview
 - 7.5.2 North America
 - 7.5.3 Europe
 - 7.5.4 Asia Pacific
 - 7.5.5 Latin America
 - 7.5.6 Middle East and Africa
- 8 North America Rare Haematology Disorders Market (2017-2032)
 - 8.1 North America Rare Haematology Disorders Market (2017-2032) by Treatment Type
 - 8.1.1 Market Overview
 - 8.1.2 Plasma Derived
 - 8.1.3 Recombinant
 - 8.2 North America Rare Haematology Disorders Market (2017-2032) by Disease Type
 - 8.2.1 Market Overview
 - 8.2.2 Langerhans Cell Histiocytosis (LCH)
 - 8.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - 8.2.4 Gaucher Disease
 - 8.2.5 Polycythemia Vera
 - 8.2.6 Others
 - 8.3 North America Rare Haematology Disorders Market (2017-2032) by Country
 - 8.3.1 United States of America
 - 8.3.2 Canada
- 9 Europe Rare Haematology Disorders Market (2017-2032)
 - 9.1 Europe Rare Haematology Disorders Market (2017-2032) by Treatment Type
 - 9.1.1 Market Overview
 - 9.1.2 Plasma Derived
 - 9.1.3 Recombinant
 - 9.2 Europe Rare Haematology Disorders Market (2017-2032) by Disease Type
 - 9.2.1 Market Overview
 - 9.2.2 Langerhans Cell Histiocytosis (LCH)
 - 9.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - 9.2.4 Gaucher Disease
 - 9.2.5 Polycythemia Vera
 - 9.2.6 Others
 - 9.3 Europe Rare Haematology Disorders Market (2017-2032) by Country
 - 9.3.1 United Kingdom
 - 9.3.2 Germany
 - 9.3.3 France
 - 9.3.4 Italy
 - 9.3.5 Others
- 10 Asia Pacific Rare Haematology Disorders Market (2017-2032)
 - 10.1 Asia Pacific Rare Haematology Disorders Market (2017-2032) by Treatment Type
 - 10.1.1 Market Overview
 - 10.1.2 Plasma Derived

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.3 Recombinant
- 10.2 Asia Pacific Rare Haematology Disorders Market (2017-2032) by Disease Type
 - 10.2.1 Market Overview
 - 10.2.2 Langerhans Cell Histiocytosis (LCH)
 - 10.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - 10.2.4 Gaucher Disease
 - 10.2.5 Polycythemia Vera
 - 10.2.6 Others
- 10.3 Asia Pacific Rare Haematology Disorders Market (2017-2032) by Country
 - 10.3.1 China
 - 10.3.2 Japan
 - 10.3.3 India
 - 10.3.4 ASEAN
 - 10.3.5 Australia
 - 10.3.6 Others
- 11 Latin America Rare Haematology Disorders Market (2017-2032)
 - 11.1 Latin America Rare Haematology Disorders Market (2017-2032) by Treatment Type
 - 11.1.1 Market Overview
 - 11.1.2 Plasma Derived
 - 11.1.3 Recombinant
 - 11.2 Latin America Rare Haematology Disorders Market (2017-2032) by Disease Type
 - 11.2.1 Market Overview
 - 11.2.2 Langerhans Cell Histiocytosis (LCH)
 - 11.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - 11.2.4 Gaucher Disease
 - 11.2.5 Polycythemia Vera
 - 11.2.6 Others
 - 11.3 Latin America Rare Haematology Disorders Market (2017-2032) by Country
 - 11.3.1 Brazil
 - 11.3.2 Argentina
 - 11.3.3 Mexico
 - 11.3.4 Others
- 12 Middle East and Africa Rare Haematology Disorders Market (2017-2032)
 - 12.1 Middle East and Africa Rare Haematology Disorders Market (2017-2032) by Treatment Type
 - 12.1.1 Market Overview
 - 12.1.2 Plasma Derived
 - 12.1.3 Recombinant
 - 12.2 Middle East and Africa Rare Haematology Disorders Market (2017-2032) by Disease Type
 - 12.2.1 Market Overview
 - 12.2.2 Langerhans Cell Histiocytosis (LCH)
 - 12.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - 12.2.4 Gaucher Disease
 - 12.2.5 Polycythemia Vera
 - 12.2.6 Others
 - 12.3 Middle East and Africa Rare Haematology Disorders Market (2017-2032) by Country
 - 12.3.1 Saudi Arabia
 - 12.3.2 United Arab Emirates

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.3 Nigeria
- 12.3.4 South Africa
- 12.3.5 Others
- 13 Patent Analysis
 - 13.1 Analysis by Type of Patent
 - 13.2 Analysis by Publication Year
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Patent Age
 - 13.5 Analysis by CPC Analysis
 - 13.6 Analysis by Patent Valuation
 - 13.7 Analysis by Key Players
- 14 Grants Analysis
 - 14.1 Analysis by Year
 - 14.2 Analysis by Amount Awarded
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Grant Application
 - 14.5 Analysis by Funding Institute
 - 14.6 Analysis by Departments
 - 14.7 Analysis by Recipient Organization
- 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.2 US FDA
 - 15.3 EU EMA
 - 15.4 INDIA CDSCO
 - 15.5 JAPAN PMDA
 - 15.6 Others
- 16 Strategic Initiatives
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership and Collaborations
 - 16.3 Analysis by Joint Ventures
 - 16.4 Analysis by Leading Players
 - 16.5 Analysis by Geography
- 17 Supplier Landscape
 - 17.1 Market Share Analysis, By Region (Top 5 Companies)
 - 17.1.1 Market Share Analysis: Global
 - 17.1.2 Market Share Analysis: North America
 - 17.1.3 Market Share Analysis: Europe
 - 17.1.4 Market Share Analysis: Asia-Pacific
 - 17.1.5 Market Share Analysis: Others
 - 17.2 Bristol-Myers Squibb Company
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Novo Nordisk
 - 17.3.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.3.2□Product Portfolio
- 17.3.3□Demographic Reach and Achievements
- 17.3.4□Mergers and Acquisitions
- 17.3.5□Certifications
- 17.4□ F. Hoffmann-La Roche Ltd
- 17.4.1□Financial Analysis
- 17.4.2□Product Portfolio
- 17.4.3□Demographic Reach and Achievements
- 17.4.4□Mergers and Acquisitions
- 17.4.5□Certifications
- 17.5□Emmaus Medical, Inc.
- 17.5.1□Financial Analysis
- 17.5.2□Product Portfolio
- 17.5.3□Demographic Reach and Achievements
- 17.5.4□Mergers and Acquisitions
- 17.5.5□Certifications
- 17.6□Pfizer Inc.
- 17.6.1□Financial Analysis
- 17.6.2□Product Portfolio
- 17.6.3□Demographic Reach and Achievements
- 17.6.4□Mergers and Acquisitions
- 17.6.5□Certifications
- 17.7□Octapharma
- 17.7.1□Financial Analysis
- 17.7.2□Product Portfolio
- 17.7.3□Demographic Reach and Achievements
- 17.7.4□Mergers and Acquisitions
- 17.7.5□Certifications
- 17.8□Novartis
- 17.8.1□Financial Analysis
- 17.8.2□Product Portfolio
- 17.8.3□Demographic Reach and Achievements
- 17.8.4□Mergers and Acquisitions
- 17.8.5□Certifications
- 17.9□Grifols
- 17.9.1□Financial Analysis
- 17.9.2□Product Portfolio
- 17.9.3□Demographic Reach and Achievements
- 17.9.4□Mergers and Acquisitions
- 17.9.5□Certifications
- 17.10□CSL Behring
- 17.10.1□Financial Analysis
- 17.10.2□Product Portfolio
- 17.10.3□Demographic Reach and Achievements
- 17.10.4□Mergers and Acquisitions
- 17.10.5□Certifications
- 17.11□Takeda

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisitions
 - 17.11.5 Certifications
 - 18 Global Rare Haematology Disorders Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
 - 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Rare Haematology Disorders Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com